August 29th 2025
Spikevax and mNEXSPIKE authorized for older adults and high-risk individuals; experts emphasize protection against severe COVID-19 outcomes.
August 29th 2025
New authorization limits shots to adults ≥65 and individuals with underlying health conditions, with ACIP set to review guidance and insurance coverage implications.
August 22nd 2025
New data show consistent late-summer and winter surges, reinforcing the need for seasonal vaccine timing and focused protection for high-risk groups.
August 22nd 2025
STOP-PASC substudy results find digital biometrics align with symptom burden, supporting their use as objective measures in long COVID research.
August 21st 2025
First-in-class IL-15 agonist aims to address persistent post-COVID symptoms by enhancing immune clearance and restoring T cell memory.
As COVID-19 Spreads Rapidly, Low- and Middle-Income Countries Face Intense Challenge
March 23rd 2020Countries around the world have struggled to keep the spread of COVID-19 in check. In countries with relatively few resources and weak public health infrastructure, the challenge is even more acute.
Read More
Could a Japanese Encephalitis Drug Prevent COVID-19?
March 19th 2020A drug known to inhibit a cellular protease TMPRSS2 could potentially be a novel therapeutic intervention for COVID-19 infections, according to German investigators who found that the cellular protein may allow entry of SARS-CoV-2 into lung cells.
Read More
2 Commerce Drive
Cranbury, NJ 08512